drugset / Trial / NCT03498222
Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin
Non-randomizedSequentialOpen-labelTreatment
Summary
iTRAP is an open-label, multi-centre, dose escalation study of ADI PEG20 in combination with atezolizumab, pemetrexed and carboplatin in patients with advanced non-squamous non-small cell lung carcinoma (NSCLC) - stage IIIB/IV.
Timeline
- Start
- 2018-06-01
- Primary completion
- 2020-01-31
- Completion
- 2021-12-31
Outcome
Outcome not reported
Stopped (Business): “Funder and IMP manufacturer withdrew support”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegargiminase | Protein / enzyme biologic | 9 mg/m2 | Intramuscular |
| Subject | Pegargiminase | Protein / enzyme biologic | 18 mg/m2 | Intramuscular |
| Subject | Pegargiminase | Protein / enzyme biologic | 36 mg/m2 | Intramuscular |
| Background | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |